12 -10 (84) 2025 - Mamajonov Z.A., Ulugbekova G.J. - PURINERGIC RECEPTOR ANTAGONISTS IN CANCER: FOCUS ON P2X7 AND P2Y12 PATHWAYS

PURINERGIC RECEPTOR ANTAGONISTS IN CANCER: FOCUS ON P2X7 AND P2Y12 PATHWAYS

Mamajonov Z.A. - Andijan State Medical Institute

Ulugbekova G.J. - Andijan State Medical Institute

Askarov I.R. - Andijan State University

Mamatova I.Y. - Andijan State Medical Institute

Resume

Purinergic receptors, especially P2X7 and P2Y12, play pivotal roles in tumor progression, immune evasion, and metastasis. Their antagonists represent a novel class of therapeutic agents with the potential to inhibit tumor growth, modulate the tumor microenvironment (TME), and restore anti-tumor immunity. However, despite promising preclinical results, their clinical translation is limited by pharmacological and toxicological challenges. This review summarizes current knowledge on P2X7 and P2Y12 receptor antagonists, their therapeutic potential, limitations, and perspectives for future cancer immunotherapy.

Keywords: P2X7 receptor, P2Y12 receptor, purinergic signaling, antagonists, tumor microenvironment, immunotherapy.

First page

69

Last page

71

For citation:Mamajonov Z.A., Ulugbekova G.J., Askarov I.R., Mamatova I.Y. - PURINERGIC RECEPTOR ANTAGONISTS IN CANCER: FOCUS ON P2X7 AND P2Y12 PATHWAYS //New Day in Medicine 10(84)2025 69-71 https://newdayworldmedicine.com/en/new_day_medicine/10-84-2025

List of References

  1. Pegoraro A, De Marchi E, Adinolfi E. P2X7 variants in oncogenesis. // Cells. 2021;10(2):413.
  2. Di Virgilio F, Giuliani AL. P2X receptors in cancer progression and metastasis. // Biochem Pharmacol. 2020;187:114350.
  3. De Marchi E, Orioli E, Pegoraro A, Sarti AC, Giuliani AL, Adinolfi E. The P2X7 receptor in hematopoietic malignancies. // Front Cell Dev Biol. 2019;7:33.
  4. Gachet C. P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cells. // Thromb Haemost. 2016;115(2):220–31.
  5. Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. // J Hematol Oncol. 2022;15(1):125.
  6. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. // Cancer Cell. 2014;20(5):576–90.
  7. Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: the state of the art. // Physiol Rev. 2018;98(3):1591–625.
  8. Sitkovsky MV, Ohta A. Targeting the hypoxia–adenosinergic signaling pathway to improve immunotherapy: opportunities and challenges. // Nat Rev Cancer. 2020;20(12):709–25.
  9. Fong L, Hotson A, Powderly J, Sznol M, Heist RS, Choueiri TK, et al. Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. // Cancer Discov. 2018;8(12):1544–57.
  10. Zahavi, D.; Hodge, J.W. Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies. // Int. J. Mol. Sci. 2023;24:8871.

    file

    download